Evaluation of participants with suspected heritable platelet function disorders including recommendation and validation of a streamlined agonist panel

Blood

Volumn 120, Issue 25, 2012, Pages 5041-5049

  Dawood, Ban B ^a   Lowe, Gillian C ^a   Lordkipanidzé, Marie ^a   Bem, Danai ^a   Daly, Martina E ^b   Makris, Mike ^b   Mumford, Andrew ^c   Wilde, Jonathan T ^d   Watson, Steve P ^a  

^a UNIVERSITY OF BIRMINGHAM   (United Kingdom)

^b UNIVERSITY OF SHEFFIELD   (United Kingdom)

^c UNIVERSITY OF BRISTOL   (United Kingdom)

^d QUEEN ELIZABETH HOSPITAL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ADRENALIN; ARACHIDONIC ACID; COLLAGEN; PROTEINASE ACTIVATED RECEPTOR 1; RISTOCETIN; THROMBOXANE A2;

ADULT; ARTICLE; ATP SECRETION TEST; CELL GRANULE; CELLULAR SECRETION; CLINICAL EVALUATION; CONTROLLED STUDY; FEMALE; GENOTYPE; HEMATOLOGICAL PROCEDURE; HUMAN; LIGHT TRANSMISSION AGGREGOMETRY; MAJOR CLINICAL STUDY; MALE; MUTATION; PHENOTYPE; PRIORITY JOURNAL; RETROSPECTIVE STUDY; SIGNAL TRANSDUCTION; THROMBOCYTE DISORDER;

EID: 84871027512     PISSN: 00064971     EISSN: 15280020     Source Type: Journal    
DOI: 10.1182/blood-2012-07-444281     Document Type: Article

References (28)

1. Cattaneo M. Inherited platelet-based bleeding disorders. J Thromb Haemost. 2003;1(7):1628-1636.
2. Nurden P, Nurden AT. Congenital disorders associated with platelet dysfunctions. Thromb Haemost. 2008;99(2):253-263. (Pubitemid 351230953)
3. Hayward CP. Diagnostic approach to platelet function disorders. Transfus Apher Sci. 2008; 38(1):65-76.
4. Hayward CP, Rao AK, Cattaneo M. Congenital platelet disorders: overview of their mechanisms, diagnostic evaluation and treatment. Haemophilia. 2006;12(Suppl 3):128-136.
5. Rao AK, Jalagadugula G, Sun L. Inherited defects in platelet signaling mechanisms. Semin Thromb Hemost. 2004;30(5):525-535. (Pubitemid 39426385)
6. Cattaneo M. Inherited platelet abnormalities. Thromb Res. 2005;115(Suppl 1):10-13.
7. Cattaneo M, Hayward CP, Moffat KA, Pugliano MT, Liu Y, Michelson AD. Results of a worldwide survey on the assessment of platelet function by light transmission aggregometry: a report from the platelet physiology subcommittee of the SSC of the ISTH. J Thromb Haemost. 2009;7(6):1029.
8. Hayward CP, Pai M, Liu Y, et al. Diagnostic utility of light transmission platelet aggregometry: results from a prospective study of individuals referred for bleeding disorder assessments. J Thromb Haemost. 2009;7(4):676-684.
9. Dawood BB, Wilde J, Watson SP. Reference curves for aggregation and ATP secretion to aid diagnose of platelet-based bleeding disorders: effect of inhibition of ADP and thromboxane A(2) pathways. Platelets. 2007;18(5):329-345. (Pubitemid 47123835)
10. Watson S, Daly M, Dawood B, et al. Phenotypic approaches to gene mapping in platelet function disorders - identification of new variant of P2Y12, TxA2 and GPVI receptors. Hamostaseologie. 2010;30(1):29-38.
11. Harrison P, Mackie I, Mumford A, et al. Guidelines for the laboratory investigation of heritable disorders of platelet function. Br J Haematol. 2011; 155(1):30-44.
12. Mani H, Luxembourg B, Klaffling C, Erbe M, Lindhoff-Last E. Use of native or platelet count adjusted platelet rich plasma for platelet aggregation measurements. J Clin Pathol. 2005;58(7):747-750. (Pubitemid 40956832)
13. Linnemann B, Schwonberg J, Mani H, Prochnow S, Lindhoff-Last E. Standardization of light transmittance aggregometry for monitoring antiplatelet therapy: an adjustment for platelet count is not necessary. J Thromb Haemost. 2008;6(4):677-683. (Pubitemid 351404936)
14. Cattaneo M, Lecchi A, Zighetti ML, Lussana F. Platelet aggregation studies: autologous platelet-poor plasma inhibits platelet aggregation when added to platelet-rich plasma to normalize platelet count. Haematologica. 2007; 92(5):694-697. (Pubitemid 350144275)
15. Lecchi A, Zighetti ML, Lussana F, Cattaneo M. Platelet aggregation studies: autologous plateletpoor plasma inhibits platelet aggregation when added to platelet-rich plasma to normalize platelet count. J Thrombosis Haemost. 2005;3(Suppl 1):P0965.
16. Nash CA, Severin S, Dawood BB, et al. Src family kinases are essential for primary aggregation by G (i)-coupled receptors. J Thromb Haemost. 2010;8(10):2273-2282.
17. Nisar S, Daly ME, Federici AB, et al. An intact PDZ motif is essential for correct P2Y12 purinoceptor traffic in human platelets. Blood. 2011; 118(20):5641-5651.
18. Mumford AD, Dawood BB, Daly ME, et al. A novel thromboxane A2 receptor D304N variant that abrogates ligand binding in a patient with a bleeding diathesis. Blood. 2010;115(2):363-369.
19. Morgan NV, Pasha S, Johnson CA, et al. A germline mutation in BLOC1S3/reduced pigmentation causes a novel variant of Hermansky-Pudlak syndrome (HPS8). Am J Hum Genet. 2006;78(1):160-166. (Pubitemid 41833170)
20. Suzuki-Inoue K, Fuller GL, Garcia A, et al. A novel Syk-dependent mechanism of platelet activation by the C-type lectin receptor CLEC-2. Blood. 2006;107(2):542-549. (Pubitemid 43076377)
21. Nieswandt B, Watson SP. Platelet-collagen interaction: is GPVI the central receptor? Blood. 2003; 102(2):449-461. (Pubitemid 36841960)
22. Kamae T, Kiyomizu K, Nakazawa T, et al. Bleeding tendency and impaired platelet function in a patient carrying a heterozygous mutation in the thromboxane A2 receptor. J Thromb Haemost. 2011;9(5):1040-1048.
23. Hirata T, Kakizuka A, Ushikubi F, Fuse I, Okuma M, Narumiya S. Arg60 to Leu mutation of the human thromboxaneA2 receptor in a dominantly inherited bleeding disorder. J Clin Invest. 1994;94(4):1662-1667.
24. Fuse I, Hattori A, Mito M, et al. Pathogenetic analysis of five cases with a platelet disorder characterized by the absence of thromboxane A2 (TXA2)-induced platelet aggregation in spite of normal TXA2 binding activity. Thromb Haemost. 1996;76(6):1080-1085.
25. Higuchi W, Fuse I, Hattori A, Aizawa Y. Mutations of the platelet thromboxane A2 (TXA2) receptor in patients characterized by the absence of TXA2-induced platelet aggregation despite normal TXA2 binding activity. Thromb Haemost. 1999; 82(5):1528-1531. (Pubitemid 29527650)
26. Hermans C, Wittevrongel C, Thys C, Smethurst PA, Van Geet C, Freson K. A compound heterozygous mutation in glycoprotein VI in a patient with a bleeding disorder. J Thromb Haemost. 2009; 7(8):1356-1363.
27. Dumont B, Lasne D, Rothschild C, et al. Absence of collagen-induced platelet activation caused by compound heterozygous GPVI mutations. Blood. 2009;114(9):1900-1903.
28. Jones ML, Murden SL, Bem D, et al. Rapid genetic diagnosis of heritable platelet function disorders using next generation sequencing: proof-of-principle with Hermansky-Pudlak syndrome. J Thromb Haemost. 2012;10(2):306-309.